Refoxy Pharmaceuticals funding news – Berlin-based Refoxy Pharmaceuticals has Secured €9.1 Million in Seed-Extension Funding

Today, the company announced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF).

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves the buildup of scar tissue (fibrosis) in the lungs and progressively limits breathing capacity.

Refoxy is taking a novel approach to tackle IPF’s complex biology by modulating a transcription factor that can orchestrate changes at multiple biological levels, with the potential to interfere with disease progression.

Dr. Victor Bustos, co-founder and CEO of Refoxy said, “We are following biology, The evidence that FOXO3 activation can be therapeutically relevant continues to grow, not only in IPF but in multiple chronic disorders. This financing brings us one step closer to leveraging FOXO3 biology for novel therapeutics.”

FOXO3 is one of the genes most robustly associated with a longer and healthier human lifespan. It helps tissues and organs fight diverse forms of stress, making it a compelling target for drug discovery. However, its complex biology has limited efforts to leverage its therapeutic potential.

Dr. Victor Bustos, along with Prof. Wolfgang Link, a world-renowned expert in FOXO3, co-founded Refoxy in partnership with Apollo Health Ventures. Their strategy focuses on identifying activators of FOXO3 through a proprietary drug discovery platform based on Prof. Link's pioneering research called F.act finder (FOXO activator finder).

Dr. Niklas Czeloth, Investment Manager at BIVF and board member at Refoxy reiterates the need for novel approaches in tackling this disease. “We are thrilled to provide funding for Refoxy's research on FOXO3 activation as a promising novel therapeutic approach. This perfectly aligns with our mission to support breakthrough developments and deliver innovative therapies to patients in need in the field of IPF.”

Dr. Anela Vukoja, Principal at Apollo and Board Member of Refoxy said, “As co-founding investors in Refoxy, we are excited about working together with the team and the strong syndicate of investors to advance its pipeline of FOXO3 enhancers in fibrosis and beyond, The company’s mission aligns with the increasing need for innovative therapies for all age-related disorders.”

Johanna Antonie Tjaden-Schulte, member of the Managing Board of NRW.BANK said, "In view of the innovative therapeutic approach being developed by Refoxy, our investment in the start-up is a good example of how promotional funding can foster innovative ideas 'Made in NRW".

About Refoxy Pharmaceuticals GmbH

Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and elicit unique therapeutic effects.